-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of $5,093.75 in Common Shares

PUBT·10/23/2026 16:32:02
AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of $5,093.75 in Common Shares
  • AIM ImmunoTech CEO, President and director Thomas K. Equels purchased 31,250 shares of common stock at $0.163 each.
  • The purchase increased his direct beneficial ownership to 158,072 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-048196), on October 23, 2026, and is solely responsible for the information contained therein.